Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subjects: Conference, Trade Show

SIWA Therapeutics To Participate in September Investor Conferences


SIWA Therapeutics, Inc., a pre-clinical stage biopharmaceutical company focused on aggressive cancers and other life-threatening diseases that should be eligible for FDA fast-tracking, will participate in two September virtual conferences.

Lewis Gruber, CEO and CSO of SIWA, will attend Biopharm America 2020, which will take place virtually from September 21-24. Gruber also will attend the Oncology Virtual Partnering event hosted by BIO and Inova Software from September 22-24. Gruber will be available to meet one-on-one with potential new partners during both conferences to discuss exciting new developments in SIWA's approach to treating both cancer and infectious diseases.

SIWA recently announced the results of a study demonstrating that 318H binds to both COVID-19 and Influenza A, thus showing promise for 318H to become a broad-spectrum antiviral drug. 318H also is being tested on bacterially-infected cells. Additionally, the company is actively partnering with a major institution in pancreatic cancer.

Investors are encouraged to request a meeting with SIWA Therapeutics through the respective scheduling portal on the conference's website. Interested parties who are not attending either upcoming conference are encouraged to reach out via email at: partners@siwatherapeutics.com

About SIWA Therapeutics, Inc.

SIWA Therapeutics, Inc. is focused on treating aggressive cancers and other life-threatening diseases that should be eligible for FDA fast-tracking. SIWA's proprietary humanized monoclonal antibody, 318H, selectively targets cells with an abnormally high level of glycolysis (the Warburg effect) and oxidative stress. Targeted cells include specifically cancer cells, senescent cells, and virally and bacterially-infected cells. 318H binds to cancer cells, senescent cells and cells infected by SARS-CoV-2 (COVID-19) and Influenza A; testing of bacterially-infected cells is in progress. We are partnering with a major institution in pancreatic cancer (a 318H in vivo PDX pancreatic cancer study in humanized mice is in process). Charles River Laboratories recently completed an in vivo 318H tolerability and pharmacokinetic studies in non-human primates in preparation for filing an IND application with the FDA. No adverse effects were observed.

More information is available at www.siwatherapeutics.com


These press releases may also interest you

at 08:15
Seagen Inc. today announced the closing of a $1.0 billion equity investment by Merck in 5.0 million newly-issued shares of Seagen common stock at a price of $200 per share. The closing occurred following expiration of the waiting period under the...

at 08:15
Popular, Inc. ("Popular") , bank holding company of Popular Bank, today announced Popular Bank's strategic realignment of its New York Metro branch network. As part of the realignment, select branches of Popular Bank will be consolidated, resulting...

at 08:15
AG & Sons, a leading independent jeweller of London, has been able to transform its customer engagement and drive sales during the COVID-19 lockdown through the use of innovative 360 videos. Allowing customers to clearly see the product from the...

at 08:14
PayPal Holdings, Inc. today announced it will invest $50 million in eight early-stage, Black and Latinx-led venture capital funds: Chingona Ventures; Fearless Fund; Harlem Capital; Precursor Ventures; Slauson & Co.; VamosVentures; Zeal Capital...

at 08:10
Popular, Inc. (the "Corporation," "Popular," "we," "us," "our") reported net income of $168.4 million for the quarter ended September 30, 2020, compared to net income of $127.6 million for the quarter ended June 30, 2020. Ignacio Alvarez, President...

at 08:10
Dine Brands Global, Inc. , the parent company of Applebee's Neighborhood Grill + Bar® and IHOP® restaurants, today announced financial results for the third quarter of 2020. "We continue to execute on our strategy to stabilize our business and...



News published on 16 september 2020 at 13:45 and distributed by: